BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32460216)

  • 1. A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma.
    Iacuzzi V; Zanchetta M; Gagno S; Poetto AS; Orleni M; Marangon E; Guardascione M; Foltran L; Posocco B; Toffoli G
    J Pharm Biomed Anal; 2020 Aug; 187():113358. PubMed ID: 32460216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.
    Allard M; Khoudour N; Rousseau B; Joly C; Costentin C; Blanchet B; Tournigand C; Hulin A
    J Pharm Biomed Anal; 2017 Aug; 142():42-48. PubMed ID: 28494338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
    Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
    J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method.
    Pang YY; Tan YL; Ho HK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1061-1062():220-224. PubMed ID: 28750235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
    Andriamanana I; Gana I; Duretz B; Hulin A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
    Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
    Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of High-Throughput Bioanalytical Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Newly Synthesized Antitumor Carbonic Anhydrase Inhibitors in Human Plasma.
    Abdel-Megied AM; Eldehna WM; Abdelrahman MA; Elbarbry FA
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33291270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring.
    Zanchetta M; Iacuzzi V; Posocco B; Bortolin G; Poetto AS; Orleni M; Canil G; Guardascione M; Foltran L; Fanotto V; Puglisi F; Gagno S; Toffoli G
    PLoS One; 2021; 16(10):e0259137. PubMed ID: 34699578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
    Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring.
    Llopis B; Robidou P; Tissot N; Pinna B; Gougis P; Aubart FC; Campedel L; Abbar B; Weil DR; Uzunov M; Gligorov J; Salem JE; Funck-Brentano C; Zahr N
    J Pharm Biomed Anal; 2021 Apr; 197():113968. PubMed ID: 33618135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast simultaneous LC/MS/MS determination of 10 active compounds in human serum for therapeutic drug monitoring in psychiatric medication.
    Sistik P; Urinovska R; Brozmanova H; Kacirova I; Silhan P; Lemr K
    Biomed Chromatogr; 2016 Feb; 30(2):217-24. PubMed ID: 26094602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Simultaneous determination of donafenib and its N-oxide metabolite in human plasma by liquid chromatography-tandem mass spectrometry].
    Wang J; Lü BH; Dai XJ; Zhang YF; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2017 Mar; 52(3):443-8. PubMed ID: 29979858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation.
    Moreno-Vicente R; Fernández-Nieva Z; Navarro A; Gascón-Crespí I; Farré-Albaladejo M; Igartua M; Hernández RM; Pedraz JL
    J Pharm Biomed Anal; 2015 Oct; 114():105-12. PubMed ID: 26037158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
    Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
    Poetto AS; Posocco B; Gagno S; Orleni M; Zanchetta M; Iacuzzi V; Canil G; Buzzo M; Montico M; Guardascione M; Basile D; Pelizzari G; Alberti M; Gerratana L; Puglisi F; Toffoli G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122985. PubMed ID: 34700133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Easy and fast LC-MS/MS determination of lidocaine and MEGX in plasma for therapeutic drug monitoring in neonates with seizures.
    ter Weijden E; van den Broek MP; Ververs FF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jan; 881-882():111-4. PubMed ID: 22192875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS.
    Ye Z; Wu L; Zhang X; Hu Y; Zheng L
    J Pharm Biomed Anal; 2021 Aug; 202():114161. PubMed ID: 34052550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of 5-HT receptor antagonists, MEFWAY and MPPF using liquid chromatography electrospray ionization tandem mass spectrometry in rat plasma and brain tissue.
    Zheng Z; Lee BH; Choi JY; Ryu YH; Bae MA; Ahn SH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():24-9. PubMed ID: 23266361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous analysis of oral anticancer drugs for renal cell carcinoma in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry.
    Takasaki S; Tanaka M; Kikuchi M; Maekawa M; Kawasaki Y; Ito A; Arai Y; Yamaguchi H; Mano N
    Biomed Chromatogr; 2018 Jun; 32(6):e4184. PubMed ID: 29283445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.